PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Case Report

Volume 2 Issue 4

Role of Semaglutide in Weight loss

Amina Wahbi*, Safi Saeed, Shareef Nada and Dalia Abuzeid

September 20, 2023

DOI : 10.56831/PSSRP-02-060

View PDF

Abstract

Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once weekly Semaglutide at a dose of 0.5-1.0 mg as an adjunct to lifestyle intervention has not been confirmed. Method: This is a clinical case report of a 29-year-old female, who tried weekly Semaglutide with lifestyle intervention. We conducted a baseline mental and physical health, and we did a biweekly follow up with her. This was over 6 months period starting from September 2022 until March 2023. Consent: Written informed consent has been obtained from the patient. Results: Our participant was able to lose 16.3 % of her body weight in 6 months, dropping her body weight from 74.3 kilograms to 61.2 kilograms, with a decrease in her body mass index from 29.3 to 23.9. With a significant improvement in mental and physical health, particularly, an improvement in her depression, generalized anxiety, and ADHD symptoms. Conclusion: In participants with overweight or obesity, 0.5-1.0 mg of Semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.

Keywords: Obesity; Semaglutide; weight loss

References

  1. Garvey WT., et al. “American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity”. Endocr Pract 22.3 (2016): 1-203.
  2. Yumuk V., et al. “European guidelines for obesity management in adults”. Obes Facts 8 (2015): 402-424.
  3. Bessesen DH and Van Gaal LF. “Progress and challenges in anti-obesity pharmacotherapy”. Lancet Diabetes Endocrinol 6 (2018): 237-248.
  4. Neeland IJ, Poirier P and Després J-P. “Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management”. Circulation 137 (2018): 1391-1406.
  5. Guh DP., et al. “The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis”. BMC Public Health 9 (2009): 88.
  6. Whitlock G., et al. “Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies”. Lancet 373 (2009): 1083-1096.
  7. Yang J, Hu J and Zhu C. “Obesity aggravates COVID-19: a systematic review and meta-analysis”. J Med Virol (2020).
  8. Sanchis-Gomar F., et al. “Obesity and outcomes in COVID-19: when an epidemic and pandemic collide”. Mayo Clin Proc 95 (2020): 1445-1453.
  9. Sumithran P., et al. “Long-term persistence of hormonal adaptations to weight loss”. N Engl J Med 365 (2011): 1597-1604.
  10. Wharton S., et al. “Obesity in adults: a clinical practice guideline”. CMAJ 192 (2020): E875-E891.
  11. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information (2020).
  12. Aroda VR., et al. “Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials”. Diabetes Metab 45 (2019): 409-418.
  13. Nauck MA and Meier JJ. “Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?”. Eur J Endocrinol 181 (2019): R211-R234.
  14. O’Neil PM., et al. “Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial”. Lancet 392 (2018): 637-649.
  15. Kushner RF., et al. “Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5”. Obesity (Silver Spring) 28 (2020): 1050-1061.
  16. Wharton S., et al. “Estimating and interpreting treatment effects in clinical trials for weight management: implications of estimands, intercurrent events and missing data”. Int J Obes 45.5 (2021): 923-933.
  17. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care 40.1 (2017): S11-S24.
  18. Banks PA., et al. “Classification of acute pancreatitis — 2012: revision of the Atlanta classification and definitions by international consensus”. Gut 62 (2013): 102-111.
  19. American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes — 2020. Diabetes Care 43.1 (2020): S89-S97.
  20. Williamson DA, Bray GA and Ryan DH. “Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?”. Obesity (Silver Spring) 23 (2015): 2319-2320.
  21. Magkos F., et al. “Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity”. Cell Metab 23 (2016): 591-601.
  22. Blundell J., et al. “Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity”. Diabetes Obes Metab 19 (2017): 1242-1251.
  23. Gabery S., et al. “Semaglutide lowers body weight in rodents via distributed neural pathways”. JCI Insight 5.6 (2020): e133429.
  24. Knudsen LB and Lau J. “The discovery and development of liraglutide and semaglutide”. Front Endocrinol (Lausanne) 10 (2019): 155-155.
  25. Friedrichsen M., et al. “The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity”. Diabetes Obes Metab (2020).
  26. Kolotkin RL and Andersen JR. “A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life”. Clin Obes 7 (2017): 273-289.
  27. Wing RR., et al. “Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes”. Diabetes Care 34 (2011): 1481-1486.
  28. Schauer PR., et al. “Bariatric surgery versus intensive medical therapy for diabetes — 3-year outcomes”. N Engl J Med 370 (2014): 2002-2013.
  29. Maciejewski ML., et al. “Bariatric surgery and long-term durability of weight loss”. JAMA Surg 151 (2016): 1046-1055.
  30. Sjöström L. “Review of the key results from the Swedish Obese Subjects (SOS) trial — a prospective controlled intervention study of bariatric surgery”. J Intern Med 273 (2013): 219-234.
  31. Courcoulas AP., et al. “Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity”. JAMA 310 (2013): 2416-2425.
  32. Benraouane F and Litwin SE. “Reductions in cardiovascular risk after bariatric surgery”. Curr Opin Cardiol 26 (2011): 555-561.
  33. McCrimmon RJ., et al. “Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial”. Diabetologia 63 (2020): 473-485.
  34. Food and Drug Administration. Saxenda (liraglutide) injection prescribing information (2020).
  35. Pi-Sunyer X., et al. “A randomized, controlled trial of 3.0 mg of liraglutide in weight management”. N Engl J Med 373 (2015): 11-22.
  36. Lyseng-Williamson KA. “Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features”. Clin Drug Investig 39 (2019): 805-819.
  37. Bettge K., et al. “Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials”. Diabetes Obes Metab 19 (2017): 336-347.
  38. Faillie J-L., et al. “Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus”. JAMA Intern Med 176 (2016): 1474-1481.
  39. Nauck MA., et al. “Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial”. Diabetes Care 42 (2019): 1912-1920.
  40. Erlinger S. “Gallstones in obesity and weight loss”. Eur J Gastroenterol Hepatol 12 (2000): 1347-1352.
  41. Quesada BM., et al. “Management of gallstones and gallbladder disease in patients undergoing gastric bypass”. World J Gastroenterol 16 (2010): 2075-2079.